At a dose of 12 mg kg−1, AZD7762 treatment did not cause hypoglycemia at 0 min, while still significantly improving glucose tolerance and insulin secretion at both 0- and 15-min postglucose injection (Extended Data Fig. 3a,b). Here, INS is linked to Hypoglycemia.